Compare CHR & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | PCSA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.2M |
| IPO Year | 2018 | 2012 |
| Metric | CHR | PCSA |
|---|---|---|
| Price | $1.36 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.4K | ★ 176.8K |
| Earning Date | 07-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $5,000.00 |
| Revenue This Year | $105.44 | N/A |
| Revenue Next Year | $30.02 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.11 |
| 52 Week High | $2.95 | $8.88 |
| Indicator | CHR | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 55.51 |
| Support Level | $0.73 | $1.80 |
| Resistance Level | $1.69 | $2.00 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 33.78 | 62.27 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.